Core Insights - Tongrentang Technology has successfully completed the trial operation of its export product workshop, marking a significant step towards the official production of its "export product production and R&D base" [1][3] Group 1: Production Capabilities - The company produces nearly 200 varieties of traditional Chinese medicine, covering over 20 dosage forms, which supports its overseas business growth [3] - The newly established export product production and R&D base has a construction area of over 1,400 square meters and is equipped with advanced pharmaceutical equipment and testing instruments [3][6] - The base is designed to meet the production and testing needs of 66 product specifications, including water honey pills, granules, and tablets, ensuring a robust supply for overseas markets [3][6] Group 2: Market Adaptation - The establishment of the export base allows for production tailored to the regulatory requirements of target markets, creating a more specialized supply system [3] - The base focuses on producing dosage forms that are more acceptable to overseas consumers, addressing cultural differences in consumption habits [3] Group 3: Quality Assurance - The trial operation tested the stability, production efficiency, and product quality, with results showing uniform granule size and excellent tablet formation [5][6] - The successful trial operation validates the "practical capabilities" of the export product workshop, enhancing the confidence in Tongrentang's international expansion [6] Group 4: Strategic Vision - The establishment of a dedicated export base enables the company to quickly respond to international market changes and systematically address the barriers faced by traditional Chinese medicine in global markets [6] - The company aims to transition from "able to export" to "good export" and ultimately to "brand export," fostering long-term trust and brand premium in international markets [6] - Future plans include optimizing production processes and advancing supporting work to achieve full production at the base, enhancing the international competitiveness of traditional Chinese medicine [6]